Clinical Trial Update: Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tipifarnib in combination with trastuzumab for metastatic breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN